SrasV1, PubMed, Curation, bibRecord, 002949

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.

Identifieur interne : 002949 ( PubMed/Curation ); précédent : 002948; suivant : 002950

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.

Auteurs : Zhi-Yong Yang [États-Unis] ; Heidi C. Werner ; Wing-Pui Kong ; Kwanyee Leung ; Elisabetta Traggiai ; Antonio Lanzavecchia ; Gary J. Nabel

Source :

Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2005.

RBID : pubmed:15642942

Descripteurs français

English descriptors

KwdEn :
- Antibodies, Viral (immunology), Antibodies, Viral (pharmacology), Antigenic Variation (genetics), Carboxypeptidases (immunology), Cell Line, Tumor, Disease Outbreaks, Epitopes, Genetic Variation (immunology), Humans, Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mutation, Missense, Peptidyl-Dipeptidase A, Receptors, Virus, SARS Virus (genetics), SARS Virus (immunology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology).
MESH :
- chemical , genetics : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Viral, Carboxypeptidases, Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , pharmacology : Antibodies, Viral.
- genetics : Antigenic Variation, SARS Virus.
- immunology : Genetic Variation, SARS Virus.
- Cell Line, Tumor, Disease Outbreaks, Epitopes, Humans, Mutation, Missense, Peptidyl-Dipeptidase A, Receptors, Virus, Spike Glycoprotein, Coronavirus.

Abstract

Molecular characterization of the severe acute respiratory syndrome coronavirus has revealed genetic diversity among isolates. The spike (S) glycoprotein, the major target for vaccine and immune therapy, shows up to 17 substitutions in its 1,255-aa sequence; however, the biologic significance of these changes is unknown. Here, the functional effects of S mutations have been determined by analyzing their affinity for a viral receptor, human angiotensin-converting enzyme 2 (hACE-2), and their sensitivity to Ab neutralization with viral pseudotypes. Although minor differences among eight strains transmitted during human outbreaks in early 2003 were found, substantial functional changes were detected in S derived from a case in late 2003 from Guangdong province [S(GD03T0013)] and from two palm civets, S(SZ3) and S(SZ16). S(GD03T0013) depended less on the hACE-2 receptor and was markedly resistant to Ab inhibition. Unexpectedly, Abs that neutralized most human S glycoproteins enhanced entry mediated by the civet virus S glycoproteins. The mechanism of enhancement involved the interaction of Abs with conformational epitopes in the hACE-2-binding domain. Finally, improved immunogens and mAbs that minimize this complication have been defined. These data show that the entry of severe acute respiratory syndrome coronaviruses can be enhanced by Abs, and they underscore the need to address the evolving diversity of this newly emerged virus for vaccines and immune therapies.

DOI: 10.1073/pnas.0409065102
PubMed: 15642942

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002949

Links to Exploration step

pubmed:15642942

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.</title>
<author><name sortKey="Yang, Zhi Yong" sort="Yang, Zhi Yong" uniqKey="Yang Z" first="Zhi-Yong" last="Yang">Zhi-Yong Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, MD 20892-3005</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Werner, Heidi C" sort="Werner, Heidi C" uniqKey="Werner H" first="Heidi C" last="Werner">Heidi C. Werner</name>
</author>
<author><name sortKey="Kong, Wing Pui" sort="Kong, Wing Pui" uniqKey="Kong W" first="Wing-Pui" last="Kong">Wing-Pui Kong</name>
</author>
<author><name sortKey="Leung, Kwanyee" sort="Leung, Kwanyee" uniqKey="Leung K" first="Kwanyee" last="Leung">Kwanyee Leung</name>
</author>
<author><name sortKey="Traggiai, Elisabetta" sort="Traggiai, Elisabetta" uniqKey="Traggiai E" first="Elisabetta" last="Traggiai">Elisabetta Traggiai</name>
</author>
<author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name>
</author>
<author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J" last="Nabel">Gary J. Nabel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:15642942</idno>
<idno type="pmid">15642942</idno>
<idno type="doi">10.1073/pnas.0409065102</idno>
<idno type="wicri:Area/PubMed/Corpus">002949</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002949</idno>
<idno type="wicri:Area/PubMed/Curation">002949</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002949</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.</title>
<author><name sortKey="Yang, Zhi Yong" sort="Yang, Zhi Yong" uniqKey="Yang Z" first="Zhi-Yong" last="Yang">Zhi-Yong Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, MD 20892-3005</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Werner, Heidi C" sort="Werner, Heidi C" uniqKey="Werner H" first="Heidi C" last="Werner">Heidi C. Werner</name>
</author>
<author><name sortKey="Kong, Wing Pui" sort="Kong, Wing Pui" uniqKey="Kong W" first="Wing-Pui" last="Kong">Wing-Pui Kong</name>
</author>
<author><name sortKey="Leung, Kwanyee" sort="Leung, Kwanyee" uniqKey="Leung K" first="Kwanyee" last="Leung">Kwanyee Leung</name>
</author>
<author><name sortKey="Traggiai, Elisabetta" sort="Traggiai, Elisabetta" uniqKey="Traggiai E" first="Elisabetta" last="Traggiai">Elisabetta Traggiai</name>
</author>
<author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name>
</author>
<author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J" last="Nabel">Gary J. Nabel</name>
</author>
</analytic>
<series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="ISSN">0027-8424</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (immunology)</term>
<term>Antibodies, Viral (pharmacology)</term>
<term>Antigenic Variation (genetics)</term>
<term>Carboxypeptidases (immunology)</term>
<term>Cell Line, Tumor</term>
<term>Disease Outbreaks</term>
<term>Epitopes</term>
<term>Genetic Variation (immunology)</term>
<term>Humans</term>
<term>Membrane Glycoproteins (genetics)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Mutation, Missense</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Receptors, Virus</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (immunology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (pharmacologie)</term>
<term>Carboxypeptidases (immunologie)</term>
<term>Flambées de maladies</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (génétique)</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Mutation faux-sens</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Protéines de l'enveloppe virale (génétique)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Récepteurs viraux</term>
<term>Variation des antigènes (génétique)</term>
<term>Variation génétique (immunologie)</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Carboxypeptidases</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Antigenic Variation</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Variation des antigènes</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Carboxypeptidases</term>
<term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Variation génétique</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Genetic Variation</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line, Tumor</term>
<term>Disease Outbreaks</term>
<term>Epitopes</term>
<term>Humans</term>
<term>Mutation, Missense</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Receptors, Virus</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Flambées de maladies</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Mutation faux-sens</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Récepteurs viraux</term>
<term>Épitopes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Molecular characterization of the severe acute respiratory syndrome coronavirus has revealed genetic diversity among isolates. The spike (S) glycoprotein, the major target for vaccine and immune therapy, shows up to 17 substitutions in its 1,255-aa sequence; however, the biologic significance of these changes is unknown. Here, the functional effects of S mutations have been determined by analyzing their affinity for a viral receptor, human angiotensin-converting enzyme 2 (hACE-2), and their sensitivity to Ab neutralization with viral pseudotypes. Although minor differences among eight strains transmitted during human outbreaks in early 2003 were found, substantial functional changes were detected in S derived from a case in late 2003 from Guangdong province [S(GD03T0013)] and from two palm civets, S(SZ3) and S(SZ16). S(GD03T0013) depended less on the hACE-2 receptor and was markedly resistant to Ab inhibition. Unexpectedly, Abs that neutralized most human S glycoproteins enhanced entry mediated by the civet virus S glycoproteins. The mechanism of enhancement involved the interaction of Abs with conformational epitopes in the hACE-2-binding domain. Finally, improved immunogens and mAbs that minimize this complication have been defined. These data show that the entry of severe acute respiratory syndrome coronaviruses can be enhanced by Abs, and they underscore the need to address the evolving diversity of this newly emerged virus for vaccines and immune therapies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15642942</PMID>
<DateCompleted><Year>2005</Year>
<Month>03</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN>
<JournalIssue CitedMedium="Print"><Volume>102</Volume>
<Issue>3</Issue>
<PubDate><Year>2005</Year>
<Month>Jan</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.</ArticleTitle>
<Pagination><MedlinePgn>797-801</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Molecular characterization of the severe acute respiratory syndrome coronavirus has revealed genetic diversity among isolates. The spike (S) glycoprotein, the major target for vaccine and immune therapy, shows up to 17 substitutions in its 1,255-aa sequence; however, the biologic significance of these changes is unknown. Here, the functional effects of S mutations have been determined by analyzing their affinity for a viral receptor, human angiotensin-converting enzyme 2 (hACE-2), and their sensitivity to Ab neutralization with viral pseudotypes. Although minor differences among eight strains transmitted during human outbreaks in early 2003 were found, substantial functional changes were detected in S derived from a case in late 2003 from Guangdong province [S(GD03T0013)] and from two palm civets, S(SZ3) and S(SZ16). S(GD03T0013) depended less on the hACE-2 receptor and was markedly resistant to Ab inhibition. Unexpectedly, Abs that neutralized most human S glycoproteins enhanced entry mediated by the civet virus S glycoproteins. The mechanism of enhancement involved the interaction of Abs with conformational epitopes in the hACE-2-binding domain. Finally, improved immunogens and mAbs that minimize this complication have been defined. These data show that the entry of severe acute respiratory syndrome coronaviruses can be enhanced by Abs, and they underscore the need to address the evolving diversity of this newly emerged virus for vaccines and immune therapies.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Zhi-yong</ForeName>
<Initials>ZY</Initials>
<AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Werner</LastName>
<ForeName>Heidi C</ForeName>
<Initials>HC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kong</LastName>
<ForeName>Wing-pui</ForeName>
<Initials>WP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Leung</LastName>
<ForeName>Kwanyee</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Traggiai</LastName>
<ForeName>Elisabetta</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lanzavecchia</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nabel</LastName>
<ForeName>Gary J</ForeName>
<Initials>GJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2005</Year>
<Month>01</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D002268">Carboxypeptidases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber>
<NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000940" MajorTopicYN="N">Antigenic Variation</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002268" MajorTopicYN="N">Carboxypeptidases</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>1</Month>
<Day>12</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>3</Month>
<Day>16</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>1</Month>
<Day>12</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId>
<ArticleId IdType="pii">0409065102</ArticleId>
<ArticleId IdType="doi">10.1073/pnas.0409065102</ArticleId>
<ArticleId IdType="pmc">PMC545557</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 May 24;361(9371):1779-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781537</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2003 Dec;1(3):209-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15035025</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 May;78(9):4552-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15078936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1986 Aug;24(2):197-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3755730</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1988 Jan 29;239(4839):476-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3277268</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Gene Ther. 1996 Aug 1;7(12):1405-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8844199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11382-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8876144</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1998 Apr;72(4):3155-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9525641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15496474</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002949 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002949 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:15642942
   |texte=   Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:15642942" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki